In the traditional Chinese medicine industry, innovation has become a major trend in the development of the industry, and the innovation and development of the industry is inseparable from the strong support
of enterprise R&D expenses.
Judging from the data disclosed by the third quarterly report of listed traditional Chinese medicine enterprises this year, traditional Chinese medicine companies are more and more willing to engage in research and development, and the cumulative R&D investment of 75 A-share Chinese medicine companies in the first three quarters was 6.
413 billion yuan, a year-on-year increase of 13.
63%.
Among them, seventy percent of traditional Chinese medicine enterprises achieved positive growth in R&D investment
.
From the perspective of R&D investment growth, there are two Chinese medicine companies with R&D investment growth rate of more than 300% in the first three quarters, namely Guizhou Sanli and Tibet Pharmaceutical, and the R&D expenses of the two companies increased by 340.
58% and 318.
18%
respectively year-on-year.
However, both companies' R&D expenses are less than
100 million yuan.
Among them, the research and development expenses of Guizhou Sanli were 11.
2657 million yuan
.
In August this year, Guizhou Sanli mentioned in a disclosed institutional research announcement that the parent company's R&D expenses in the first half of this year were mainly the process improvement and quality improvement of the open-throat sword, and part of it was mainly the R&D expenses
of Xiaoqi Pharmaceutical.
It is understood that open-throat sword spray is an exclusive variety
of Guizhou Sanli.
In February this year, Guizhou Sanli mentioned in the announcement, "At present, the open-throat sword spray (children's type) has covered more than 95% of children's specialized hospitals and hospitals containing pediatrics, and the second and third terminals will be the main development direction
in the future.
" At present, the development time of open-throat sword spray in the hospital side is relatively short, and the coverage rate of the hospital end is low, and the development of the hospital end and the second and third terminals will be equally focused in
the future.
”
Xiaoqian Pharmaceutical is an Internet start-up based on medical technology invested and established by Guizhou Sanli in July 21, mainly cooperating with hospitals to carry out Internet hospitals, online diagnosis and treatment, chronic disease management and other businesses
.
Tibet Pharmaceutical's R&D expenses in the first three quarters of this year were also below 100 million yuan, reaching 79.
909 million yuan, and the company's R&D expenses in the first three quarters increased mainly due to the impact of its vaccine project development expenditure of 54.
0233 million yuan in the current period
.
In addition, the R&D expenses of Jianmin Group, Wellcome Pharmaceutical, ST Kangmei and Kanghui Pharmaceutical all increased by more than 60% year-on-year, but the R&D expenses were not much, all between one million and ten million yuan
.
The industry believes that small and medium-sized pharmaceutical enterprises generally have the problem of relatively single products and weak market competitiveness, resulting in weak R&D foundation and low R&D investment costs, but from the perspective of the investment intensity of traditional Chinese medicine enterprises this year, it has been greatly improved compared with the same period of last year, which will inject impetus
into the subsequent innovation of enterprises.
From the perspective of some large traditional Chinese medicine enterprises, R&D investment is relatively high, with 13 R&D investment exceeding 100 million yuan, including Baiyunshan, Tasly and Yiling Pharmaceutical
.
Among them, Baiyunshan's R&D expenses in the first three quarters were 664 million yuan, and the company has three major sectors: big health, big southern medicine and big business, mainly focusing on new drug development, generic drug consistency evaluation, product secondary development and food and health food development
.
Continuous R&D investment has injected innovation power into the company, and by the end of 2021, Baiyunshan had a total of 119 products under development
.
Tasly's R&D expenses in the first three quarters also approached 600 million yuan, reaching 591 million yuan, a year-on-year increase of 49.
02%.
In the first three quarters of this year, the company's modern traditional Chinese medicine and biological drugs achieved continuous growth, of which modern traditional Chinese medicine increased by 7.
70%
year-on-year.
The traditional Chinese medicine business has also made a number of progress under high R&D investment, such as the approval of Jiuwei Hua Banwan Pill, a Class 1.
1 innovative Chinese medicine drug, and the Tasly Modern Chinese Medicine R&D Innovation Base has also been selected as the "Science and Technology Innovation China" Innovation Base of the Industry-University-Research Collaboration category of the China Association for Science and Technology
.
Yiling Pharmaceutical's R&D expenses in the first three quarters were 552 million yuan
.
The company focuses on innovative Chinese medicine research and development, a large amount of capital injection for the company's scientific research and innovation to provide fertile soil, the company has developed and listed 13 innovative patented traditional Chinese medicines, covering cardiovascular and cerebrovascular diseases, respiratory diseases, tumors, diabetes and other major diseases
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
